Ionis Pharmaceuticals
bepirovirsen
chronic hepatitis B
Countdown
112days
FDA decision · Oct 26, 2026
What's at stake
The FDA's approval decision on bepirovirsen for chronic hepatitis B is due Oct 26, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“NDA filing accepted by FDA for Priority Review with PDUFA date of October 26, 2026”